Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT00057811
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:35:50.524911+00:00
Published At
2014-08-22T00:00:00+00:00
Record Updated At
2014-09-19
Results Posted At
2014-08-22
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Stage I Childhood Large Cell Lymphoma", "Stage I Childhood Small Noncleaved Cell Lymphoma", "Stage II Childhood Large Cell Lymphoma", "Stage II Childhood Small Noncleaved Cell Lymphoma", "Stage III Childhood Large Cell Lymphoma", "Stage III Childhood Small Noncleaved Cell Lymphoma", "Stage IV Childhood Large Cell Lymphoma", "Stage IV Childhood Small Noncleaved Cell Lymphoma", "Untreated Childhood Acute Lymphoblastic Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2014-09-19"
protocolSection.identificationModule.nctId
"NCT00057811"
protocolSection.identificationModule.officialTitle
"A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2014-08-22"

Study condition terms

  • Childhood Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
  • Childhood Diffuse Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Childhood Immunoblastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage I Childhood Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage I Childhood Small Noncleaved Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage II Childhood Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage II Childhood Small Noncleaved Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage III Childhood Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage III Childhood Small Noncleaved Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage IV Childhood Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Stage IV Childhood Small Noncleaved Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Untreated Childhood Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.